Key result
PUFA analogs stabilize KCNQ1 voltage sensors better than linoleic acid despite poorer Site II fit.
Why the study?
KCNQ1 loss-of-function mutations cause LQTS, and while PUFAs and PUFA analogs activate KCNQ1, their mechanistic interactions at distinct binding sites required clarification for therapeutic development.
PUFA analogs linoleic-glycine and linoleic-tyrosine activate the KCNQ1 channel more effectively at the voltage sensor (Site I) but less effectively at the pore (Site II) compared to linoleic acid, providing molecular models for future drug development for Long QT Syndrome.
These analogs may guide KCNQ1-targeted Long QT therapies; leaves open translation from channel models to clinical use.
The KCNQ1 channel is important for the repolarization phase of the cardiac action potential. Loss of function mutations in KCNQ1 can cause long QT syndrome (LQTS), which can lead to cardiac arrythmia and even sudden cardiac death. We have previously shown that polyunsaturated fatty acids (PUFAs) and PUFA analogs can activate the cardiac KCNQ1 channel, making them potential therapeutics for the treatment of LQTS. PUFAs bind to KCNQ1 at two different binding sites: one at the voltage sensor (Site I) and one at the pore (Site II). PUFA interaction at Site I shifts the voltage dependence of the channel to the left, while interaction at Site II increases maximal conductance. The PUFA analogs, linoleic-glycine and linoleic-tyrosine, are more effective than linoleic acid at Site I, but less effective at Site II. Using both simulations and experiments, we find that the larger head groups of linoleic-glycine and linoleic-tyrosine interact with more residues than the smaller linoleic acid at Site I. We propose that this will stabilize the negatively charged PUFA head group in a position to better interact electrostatically with the positively charges in the voltage sensor. In contrast, the larger head groups of linoleic-glycine and linoleic-tyrosine compared with linoleic acid prevent a close fit of these PUFA analogs in Site II, which is more confined. In addition, we identify several KCNQ1 residues as critical PUFA-analog binding residues, thereby providing molecular models of specific interactions between PUFA analogs and KCNQ1. These interactions will aid in future drug development based on PUFA-KCNQ1 channel interactions.
No takes yet. Share an insight, caveat, or question.
Jowais et al. (2023) studied Long QT syndrome (LQTS). PUFA analogs (linoleic-glycine and linoleic-tyrosine) vs. Linoleic acid was evaluated on KCNQ1 channel binding and activation mechanisms. PUFA analogs linoleic-glycine and linoleic-tyrosine interact with more residues at KCNQ1 Site I than linoleic acid, stabilizing the voltage sensor, but have a poorer fit at Site II.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: